<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428883</url>
  </required_header>
  <id_info>
    <org_study_id>FARM5X8AWM</org_study_id>
    <nct_id>NCT00428883</nct_id>
  </id_info>
  <brief_title>High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis</brief_title>
  <official_title>Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <brief_summary>
    <textblock>
      -  Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder
           characterized by fibrosis of the skin and visceral organs that alters every aspect of an
           individual life

        -  Although some features of scleroderma phenotype are well established and represent the
           hallmarks of the disease, the primary cause is not fully delineated, though both
           endothelial cell damage, immunological abnormalities and excessive extracellular matrix
           production are well-documented

        -  Recently, excessive oxidative stress has been implicated in the pathogenesis of
           scleroderma

        -  N-acetylcysteine (NAC) exhibits direct and indirect antioxidant properties. Its free
           thiol group is capable of interacting with the electrophilic groups of ROS. This
           interaction with ROS leads to intermediate formation of NAC thiol, with NAC disulphide
           as a major end product. The net result is a decrease of the concentrations of OH-, H2O2,
           and HOCl. In addition, NAC exerts an indirect antioxidant effect related to its role as
           a glutathione (GSH) precursor. It serves as a central factor in protecting against
           internal toxic agents.

        -  In view of these considerations we expect that NAC can confer substantial benefit in
           patients with scleroderma reducing skin fibrosis in view of its antioxidant properties,
           and we have decided to conduct a double blind, multicenter trial to establish whether
           NAC could ameliorate skin fibrosis in scleroderma patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date>February 2009</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the reduction of skin thickness</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluated by the modified Rodnan skin score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>scleroderma disease activity assessed as established</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient physical and emotional well-being (VAS, HAQ, SF36)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory evidence of skin fibroblast activation;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the levels of Glutathione and of oxidized glutathione (GSSG).</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine (NAC)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of early diffuse scleroderma

          -  ability to give an informed consent

          -  use of an acceptable method of birth control (if women in childbearing age). Pregnancy
             will be ruled out before study beginning.

        Exclusion Criteria:

          -  connective tissue diseases or other autoimmune diseases other than SSc;

          -  history of intolerance to the study drugs;

          -  severe cardiac failure (NYHA &gt;=3 or left ventricular ejection fraction &lt;40%), recent
             (&lt;6 months) history of myocardial infarction; symptomatic ischemic myocardial disease,
             ventricular tachyarrhythmia, atrial fibrillation;

          -  resting PaO2 &lt;60mm/hg

          -  creatinine clearance below 90ml/h

          -  severe hepatic failure

          -  bronchial asthma h. hemorrhagic diathesis i. pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Gabrielli, MD,professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università Politecnica delle Marche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Gabrielli, MD,Professor</last_name>
    <phone>+390712206101</phone>
    <email>a.gabrielli@univpm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni Pomponio, MD</last_name>
    <phone>+390715964209</phone>
    <email>g.pomponio@ao-umbertoprimo.marche.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Università politecnica delle marche</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Gabrielli, MD,professor</last_name>
      <phone>+390712206104</phone>
      <email>a.gabrielli@univpm.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Pomponio, MD</last_name>
      <phone>+390715964205</phone>
      <email>g.pomponio@ao-umbertoprimo.marche.it</email>
    </contact_backup>
    <investigator>
      <last_name>Armando Gabrielli, MD,professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università de L’Aquila</name>
      <address>
        <city>Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Giacomelli, Ph</last_name>
      <email>roberto.giacomelli@cc.univaq.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Giacomelli, MD,professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Matucci-Cerinic, MD,professor</last_name>
      <email>cerinic@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Marco Matucci-Cerinic, MD,professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Valentini, MD,professor</last_name>
      <email>gabriele.valentini@unina2.it</email>
    </contact>
    <investigator>
      <last_name>Gabriele Valentini, MD,professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco Ferraccioli, MD,professor</last_name>
    </contact>
    <investigator>
      <last_name>Gianfranco Ferraccioli, MD,professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <last_update_submitted>January 29, 2007</last_update_submitted>
  <last_update_submitted_qc>January 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2007</last_update_posted>
  <keyword>Scleroderma, Systemic</keyword>
  <keyword>Scleroderma, Diffuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

